Sun Pharma Advanced Research wins ₹28 crore CENVAT credit refund case in CESTAT
On Thursday (October 1), shares of Sun Pharma Advanced Research Company Ltd ended at ₹194.90, down by ₹2.30, or 1.17%, on the BSE.
Sun Pharma Advanced Research Company Ltd on Sunday said the Customs, Excise & Service Tax Appellate Tribunal , Mumbai, has upheld an earlier order in favour of the company and confirmed its entitlement to a refund of accumulated CENVAT credit worth ₹27.51 crore, along with consequential interest, where applicable.The tribunal dismissed the Revenue's appeal, bringing the litigation disclosed by the company before CESTAT to a decision in SPARC's favour. The company said the tribunal upheld the Order-in-Appeal dated April 27, 2018, which was passed in favour of SPARC."The Tribunal has upheld the Order-in-Appeal dated 27.04.2018 passed in favour of the Company and confirmed the company's entitlement to refund of accumulated CENVAT credit along with consequential interest, where applicable for an amount of Rs 2751 Lakh. Accordingly, the litigation stands decided in favour of the company and the Revenue's appeal has been dismissed," according to a stock exchange filing.The refund pertains to accumulated CENVAT credit of ₹2,751 lakh, along with consequential interest, where applicable.
SPARC had disclosed the ongoing litigation in an intimation dated August 14, 2023. The company said the litigation stands decided in its favour following the tribunal's order and the dismissal of the Revenue's appeal.ALSO READ | Sun Pharma Advanced Research investors lose ₹970 crore in nine sessions, Rekha Jhunjhunwala cuts stake in December quarterThe company said there was no litigation against key management personnel, its promoter or ultimate person in control in relation to the matter. It also said the settlement provisions were not applicable.First Quarter ResultsThe company reported a net loss of ₹20.78 crore for Q1, compared with a loss of ₹51.87 crore in the year-ago quarter. Revenue rose to ₹40 crore from ₹9.6 crore a year earlier.The company’s EBITDA loss also narrowed to ₹27 crore, compared with an EBITDA loss of ₹48.2 crore in the corresponding quarter last year.Sun Pharma Advanced Research Company is a pharmaceutical research and development company focused on developing innovative medicines and therapies.ALSO READ | SPARC shares advance after stock nearly halves in a 14-day losing streakOn Thursday , shares of Sun Pharma Advanced Research Company Ltd ended at ₹194.90, down by ₹2.30, or 1.17%, on the BSE.
Related Stories
Gold prices near Rs 1.47 lakh/10 grams, silver falls by Rs 1,144/kg as traders await Fed rate signals. What lies ahead?
Gold prices edged lower while silver fell on MCX as investors awaited the US Federal Reserves upcoming policy decision for clues on interest rates. Traders expect rates to remain unchanged in October, with a possible hike in December. Analysts say dollar strength may cap golds upside, while central bank buying supports longer-term prices.
Infosys, TCS, Coforge, HCL Tech, TechM, Sagility: Selective rerating ahead, Jefferes shares target prices -
Infosys and TCS are seen as large IT companies offering 20 per cent-plus rerating potential in the best case. Sagility stands out among mid-sized companies, Jefferies said.
YES Bank share price targets: Goldman Sachs, Citi among 10 brokers with 'Sell' calls; what Nomura, others say -
Goldman Sachs has a target price of Rs 17 for YES Bank, while Citi sees the stock falling to Rs 16.50. Kotak Institutional Equities and Nuvama Institutional Equities have even lower targets of Rs 16.